AnaptysBio, Inc.
10421 Pacific Center Court
Suite 200
San Diego
California
92121
United States
Tel: 858-362-6295
Fax: 858-362-6296
Website: http://www.anaptysbio.com/
Email: info@anaptysbio.com
About AnaptysBio, Inc.
AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States.
Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. We are advancing etokimab, our proprietary anti-interleukin-33 antibody, for the treatment of atopic dermatitis, eosinophilic asthma and chronic rhinosinusitis with nasal polyps.
In addition, we are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).
Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.
Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene.
Stock Exchange: NASDAQ
Stock Symbol: ANAB
84 articles with AnaptysBio, Inc.
-
AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference
11/13/2020
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the 2020 Jefferies London Virtual Healthcare Conference
-
AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates
11/4/2020
Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe Generalized Pustular Psoriasis (GPP) announced in October 2020
-
AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration
10/26/2020
Dostarlimab royalties to AnaptysBio increase from 4-8% to 8-25% of global net sales, with first US approval in endometrial cancer anticipated in Q4 2020 Additional 1% royalty to AnaptysBio on GSK’s global net sales of Zejula™ (niraparib) starting January 2021 GSK to pay one-time cash payment of $60MM to AnaptysBio within 30 days GSK obtains freedom to develop and commercialize Zejula™ in combination with third party molecules $75MM in dostarlimab FDA BLA and EMA MAA regulatory filing and app
-
AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
10/13/2020
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced positive topline data from an interim analysis of its Phase 2 clinical trial of imsidolimab
-
AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference
9/11/2020
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the 2020 Cantor Global Virtual Healthcare Conference on Thursday, September 17, 2020 at 12:00 p.m. ET
-
AnaptysBio Reports Top-Line Data from Interim Analysis of ECLIPSE Phase 2 Clinical Trial of Etokimab in Chronic Rhinosinusitis with Nasal Polyps
8/10/2020
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immune-oncology indications, today reported top-line data from a week 8 interim analysis of the Company’s ongoing ECLIPSE Phase 2 clinical trial of etokimab,
-
AnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates
8/10/2020
Interim 8-Week Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Did Not Demonstrate Statistical Significance For Either Q4W or Q8W Versus Placebo; Company Plans To Assess Path Forward for Etokimab After Complete 16-Week Trial Data by year-end 2020 Following Orphan Drug Designation by the FDA, Additional Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis on Track for Fourth Q
-
AnaptysBio to Present at The 2020 Wedbush PacGrow Healthcare Conference
8/5/2020
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the 2020 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2020 at 2:55 p.m. ET.
-
AnaptysBio Appoints Dr. Paul F. Lizzul As Chief Medical OfficerDermatology Physician-Scientist To Lead Wholly-Owned Pipeline Advancement
7/31/2020
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Paul F. Lizzul, M.D., Ph.D. as Chief Medical Officer. “Paul’s extensive expertise in the development of immune-modulating therapeutics will be instrumental to the advancement of Anapty
-
AnaptysBio Expands Executive Leadership TeamAppoints Dennis Mulroy as Chief Financial Officer and Eric Loumeau as Chief Operating Officer
7/15/2020
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Dennis Mulroy as Chief Financial Officer and Eric Loumeau as Chief Operating Officer. “Dennis and Eric are outstanding business and finance leadership additions to our executive team,”
-
AnaptysBio Announces Orphan Drug Designation of Imsidolimab For Treatment of Generalized Pustular Psoriasis
7/8/2020
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for imsidolimab, the company’s proprietary anti-interleukin-36 receptor (IL-36R) antibody, for the treatment of patients with GPP.
-
AnaptysBio Announces First Quarter 2020 Financial Results and Provides Pipeline Updates
5/6/2020
Interim Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Anticipated in Third Quarter of 2020, Decided to Over-Enroll Trial Due to COVID-19
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
4/12/2020
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc.
-
AnaptysBio Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Pipeline Updates
3/2/2020
AnaptysBio today reported operating results for the fourth quarter and year ended December 31, 2019 and provided pipeline updates.
-
AnaptysBio to Present at The Cowen and Company 40th Annual Health Care Conference
2/25/2020
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the Cowen and Company 40th Annual Health Care Conference on Tuesday, March 3, 2020
-
AnaptysBio to Present at J.P. Morgan Annual Healthcare Conference
1/8/2020
J.P. Morgan 38th Annual Healthcare Conference on Wednesday, Jan. 15, 2020 at 2:30 p.m. PT at the Westin St. Francis in San Francisco.
-
The seven featured companies are the top companies headquartered in Biotech Beach based on 2018 revenue.
-
AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint
11/8/2019
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced topline data from its ATLAS trial, a Phase 2b randomized, double-blinded, placebo-controlled, multi-dose study in approximately 300 adult patients treated with etokimab in moderate-to-severe atopic dermatitis.
-
AnaptysBio Announces Third Quarter 2019 Financial Results and Provides Pipeline Updates
11/8/2019
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the third quarter ended September 30, 2019 and provided pipeline updates.
-
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im...